Imperial College London
Portrait Picture

ProfessorGrahamCooke

Faculty of Medicine, Department of Infectious Disease

Vice Dean (Research); Professor of Infectious Diseases
 
 
 
//

Contact

 

g.cooke

 
 
//

Location

 

Infectious Diseases SectionMedical SchoolSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@inproceedings{Ingiliz:2021:10.1111/hiv.13183,
author = {Ingiliz, P and Maurice, J and Shimakawa, Y and Grunwald, S and Tsochatzis, E and Bhagani, S and Boesecke, C and Rockstroh, JK and Anyanechi, M and Kidd, O and Garvey, L and Khamri, W and Goldin, R and Forlano, R and Thursz, M and Cooke, GS and Nelson, M and Lemoine, M},
doi = {10.1111/hiv.13183},
pages = {191--191},
publisher = {Wiley},
title = {Impact of an add-on strategy of the C-C chemokine receptor 5 (CCR5) antagonist maraviroc on hepatic inflammation in HIV-infected individuals with non-alcoholic steatohepatitis: a paired-liver biopsy proof-of-concept study},
url = {http://dx.doi.org/10.1111/hiv.13183},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - CPAPER
AB  - Introduction. Non-alcoholic steatohepatitis (NASH) is of concern in an agingand antiretroviral therapy (ART)-pretreated HIV-infected population. Notherapeutic agent has yet been licensed for the treatment of NASH in orderto reduce hepatic inflammation, steatosis, or liver fibrosis. The CCR5receptor antagonist maraviroc is an approved HIV drug, but hepatic CCR5inhibition has also been suggested to reduce hepatic inflammation andfibrogenesis in animal models. This study aimed to investigate the impact ofa maraviroc add-on strategy on hepatic inflammation in ART-treated HIVmono-infected individuals with NASH.Methods. The MASH study (Maraviroc-Add on for Steatohepatitis in HIVinfected patients) was a single-arm, open-label trial conducted across 5sites in Germany and the United Kingdom. HIV-infected individuals withbiopsy proven NASH were invited to add maraviroc BID to their existing,suppressive ART regimen for 48 weeks, and undergo a second liver biopsythereafter. Patients had immunologic, cytokine, metabolic, and histologicassessment at baseline and end of treatment (EOT).Results. Overall, 24 subjects were screened, and 13 completed the study and were analyzed. All participants were male,median age 50.5 years [45.5-55.5], baseline BMI 30.66 kg/m2 [27.92-33.63]; 83.3% (10/12) had insulin resistance. Atbaseline, 11/13 patients (85%) had fibrosis >1 (Metavir). At EOT no significant changes in the hepatic immune cell infiltrate(CD4/CD8/CD68) were observed, however, the NAS score decreased non significantly from 4.077 ± 0.76 at baseline to 3.64 ±0.51 at EOT (p = 0.125). At week 48, 7/11 patients (63%) showed significant fibrosis> stage 1, EOT BMI was similar comparedto baseline. Add-on MVC had no significant impact on inflammatory markers or lipid metabolism.
AU  - Ingiliz,P
AU  - Maurice,J
AU  - Shimakawa,Y
AU  - Grunwald,S
AU  - Tsochatzis,E
AU  - Bhagani,S
AU  - Boesecke,C
AU  - Rockstroh,JK
AU  - Anyanechi,M
AU  - Kidd,O
AU  - Garvey,L
AU  - Khamri,W
AU  - Goldin,R
AU  - Forlano,R
AU  - Thursz,M
AU  - Cooke,GS
AU  - Nelson,M
AU  - Lemoine,M
DO  - 10.1111/hiv.13183
EP  - 191
PB  - Wiley
PY  - 2021///
SN  - 1464-2662
SP  - 191
TI  - Impact of an add-on strategy of the C-C chemokine receptor 5 (CCR5) antagonist maraviroc on hepatic inflammation in HIV-infected individuals with non-alcoholic steatohepatitis: a paired-liver biopsy proof-of-concept study
UR  - http://dx.doi.org/10.1111/hiv.13183
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000711388200211&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://onlinelibrary.wiley.com/doi/10.1111/hiv.13183
UR  - http://hdl.handle.net/10044/1/93963
ER  -
Download